INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DURATION OF FIRST REMISSION
Author(s): ,
Matthias Stelljes
Affiliations:
Universitätsklinikum Münster,Münster,Germany
,
Elias Jabbour
Affiliations:
University of Texas MD Anderson Cancer Center,Houston TX,United States
,
Anjali Advani
Affiliations:
Cleveland Clinic Taussig Cancer Institute,Cleveland OH,United States
,
Daniel J DeAngelo
Affiliations:
Dana-Farber Cancer Institute,Boston MA,United States
,
David I Marks
Affiliations:
University Hospitals Bristol,Bristol,United Kingdom
,
Wendy Stock
Affiliations:
University of Chicago,Chicago IL,United States
,
Susan O’Brien
Affiliations:
University of California, Irvine Medical Center,Orange CA,United States
,
Ryan D Cassaday
Affiliations:
University of Washington School of Medicine and Fred Hutchinson Cancer Research Center,Seattle WA,United States
,
Tao Wang
Affiliations:
Pfizer Inc,Groton CT,United States
,
Alexander Neuhof
Affiliations:
Pfizer Pharma GmbH,Berlin,Germany
,
Erik Vandendries
Affiliations:
Pfizer Inc,Cambridge MA,United States
Hagop Kantarjian
Affiliations:
University of Texas MD Anderson Cancer Center,Houston TX,United States
EHA Library. Stelljes M. Jun 15, 2019; 267250; PS949
Prof. Dr. Matthias Stelljes
Prof. Dr. Matthias Stelljes
Contributions
Abstract

Abstract: PS949

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
In R/R ALL, data are limited supporting targeted therapies like InO as first salvage in patients (pts) who achieved a long duration of first complete remission (CR1). InO, a calicheamicin-conjugated antibody, targets CD22 on ALL blasts.

Aims
Here we report outcomes in pts with ALL in first salvage (S1) who had a long CR1 before receiving InO vs standard of care chemotherapy (SC).

Methods
Adults with CD22+ R/R ALL, stratified by salvage and length of remission (CR1 ≥ or < 12 mos), were randomized to receive InO (n=164) or SC (n=162). Methods were previously described (Kantarjian et al, NEJM 2016), with data shown up to the last patient last visit (January 4, 2017). Outcomes including complete remission (CR)/CR with incomplete hematologic recovery (CRi) and overall survival (OS) were determined for S1 pts who achieved CR1 ≥ 12 mos and CR1 ≥ 18 mos.

Results
For S1 pts with CR1 ≥ 12 mos or CR1 ≥ 18 mos, InO and SC arms had generally comparable baseline characteristics. For S1 pts with CR1 ≥ 12 mos and CR1 ≥ 18 mos, fewer pts had received a prior stem cell transplant in the InO vs SC arm (10.4% vs 25.0%  and 9.7% vs 21.4%). For S1 pts with CR1 ≥ 12 mos and CR1 ≥ 18 mos respectively, InO vs SC treatment led to a higher CR/CRi rate (85.4% vs 27.5% [P<0.0001] and 83.9% vs 32.1% [P<0.0001]) and improved OS (HR=0.547 [P=0.0086] and 0.504 [P=0.0163]), with veno-occlusive liver disease reported in 12.5% and 12.9% of InO pts.

Conclusion
Improved outcomes were seen with InO vs SC among S1 pts who had a long first complete remission (CR1 ≥ 12 mos or CR1 ≥ 18 mos), supporting the benefit of InO vs SC in this population.

Session topic: 2. Acute lymphoblastic leukemia - Clinical

Keyword(s): Acute lymphoblastic leukemia, Salvage therapy, Targeted therapy

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies